Cancer chemotherapy has been limited by its side effects and multidrug resistance (MDR), the latter of which is partially caused by drug efflux from cancer cells. Thus, targeted drug delivery systems that can circumvent MDR are needed. Here, we report multifunctional DNA nanoflowers (NFs) for targeted drug delivery to both chemosensitive and MDR cancer cells that circumvented MDR in both leukemia and breast cancer cell models. NFs are self-assembled via potential co-precipitation of DNA and magnesium pyrophosphate generated by rolling circle replication, during which NFs are incorporated using aptamers for specific cancer cell recognition, fluorophores for bioimaging, and doxorubicin (Dox)-binding DNA for drug delivery. NF sizes are tunable (down to ~200 nm in diameter), and the densely packed drug-binding motifs and porous intrastructures endow NFs with a high drug-loading capacity (71.4%, wt/wt). Although the Doxloaded NFs (NF-Dox) are stable at physiological pH, drug release is facilitated under acidic or basic conditions. NFs deliver Dox into target chemosensitive and MDR cancer cells, preventing drug efflux and enhancing drug retention in MDR cells. NF-Dox induces potent cytotoxicity in both target chemosensitive cells and MDR cells, but not in nontarget cells, thus concurrently circumventing MDR and reducing side effects. Overall, these NFs are promising tools for circumventing MDR in targeted cancer therapy.
Introduction
Chemotherapy is one of the principal modalities of cancer therapy. However, conventional chemotherapy has often been impeded by side effects resulting from nonspecific drug delivery [1] and multidrug resistance (MDR) [2] . Nonspecific drug delivery is not only inefficient, but also causes toxicity in healthy tissues when drugs are systemically administered, resulting in suboptimal antitumor efficacy and side effects [1] . For example, doxorubicin (Dox), an anthracycline drug widely used in cancer chemotherapy [3] , can cause cardiomyopathy, which leads to lethal congestive heart failure [4] . Suboptimal cancer suppression and cancer recurrence can also be attributed to MDR, which often results from drug efflux from cancer cells [5, 6] . Drug efflux is driven by adenosine triphosphatebinding cassette (ABC) transporter proteins, such as P-glycoprotein (P-gp or ABCB1) and ABCG2, which are overexpressed in many types of cancer cells. These transmembrane proteins have distinctive nucleotide-binding domains (NBDs) that hydrolyze ATP to generate energy for the active transport of various substrates across the membrane [7] . Hundreds of compounds as small as 330 Daltons and up to 4,000 Daltons can be substrates of ABC transporters, making cancer chemotherapy rather challenging. Other factors that contribute to MDR include acquiring MDR during therapy, enzymatic drug inactivation [2, 6] , cancer heterogeneity, and cancer stem cells [8] . The pharmacokinetic effect of MDR limits effective drug delivery into subcellular organelles, which many drugs must reach to achieve optimal therapy. Increasing therapeutic efficacy by escalating drug dose can produce an array of side effects. Thus, achieving optimal chemotherapy under these conditions presents a great challenge.
As an alternative, targeted drug delivery seeks to deliver drugs only to cancer cells [9] . Active targeting utilizes molecular recognition ligands, ranging from antibodies [10] and aptamers [11] to growth factors and vitamins [12] , to specifically bind to overexpressed cognate receptors on target cancer cells. DNA aptamers are single-stranded DNA that can specifically bind to cognate targets. Recently, our group developed cell-Systematic Evolution of Ligands by EXponential enrichment (SELEX) [13, 14] to select aptamers for living cells in various cancers [11, [15] [16] [17] . These aptamers possess many remarkable features, such as facile screening against various targets, strong binding affinity, receptor-mediated cell internalization, and low cytotoxicity and immunogenicity [18, 19] , making aptamers excellent targeting ligands for targeted drug delivery [19] . Another mode, passive targeting, utilizes drug nanocarriers to exploit the tumor-enhanced permeation and retention (EPR) effect resulting from leaky blood vasculature and poor lymphatic drainage [20] . This allows nanocarriers to easily penetrate the tumor vasculature and have prolonged tumor retention times, thus enabling specific tissue targeting and improved drug delivery. Nanocarriers generally show high loading capacity of drugs, protection of loaded drugs, and ease of biofunctionalization [9] . Remarkably, many nanocarriers have been reported to circumvent MDR. This distinction arises from their high drug payload capacity and protection of loaded drugs against cell efflux or enzymatic inactivation. The use of nanocarriers for targeted drug delivery has provided a new means of circumventing MDR, in addition to other MDR-inhibiting modalities, such as inhibitors of ABC transporters and polymers [2, 5, 9, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] .
DNA nanotechnology has enabled the development of various DNA nanocarriers for drug delivery [22, [32] [33] [34] [35] [36] [37] based on the unique features of DNA such as sequence programmability, automated synthesis and modification, and intrinsic functionalities (e.g., aptamers for recognition and DNA antisenses for therapy [29] ). Previously, we reported a noncanonical approach for the self-assembly of DNA nanoflowers (NFs), which are DNA nanogels by their nature of hydrogel. In contrast to the conventional assembly of DNA nanostructures by hybridization [22, [32] [33] [34] [35] [36] , NFs were self-assembled by co-precipitation of magnesium pyrophosphate and DNA, both of which are generated during rolling circle replication (RCR), an enzymatic reaction that efficiently generates repetitive single-stranded DNA using a designer circular DNA as a template [37, 38] . Using this customized design of RCR templates, NFs can be constructed to have many advantageous properties, including simple DNA design and preparation, size tunability, and resistance to enzymatic degradation and denaturation. NFs can be assembled from any DNA Nano Res. 2015, 8(11) : 3447-3460 templates suitable for RCR, allowing for customized incorporation of DNA functionalities, including DNA motifs for drug loading and aptamers for specific recognition and internalization into target cancer cells.
Taking advantage of these features, we report the development of DNA NFs for targeted drug delivery to both chemosensitive and chemoresistant cancer cells and the circumvention of MDR in both leukemia and breast cancer cell models. During NF assembly, NFs were concurrently integrated with aptamers for cancer cell-specific recognition and internalization, fluorophores for bioimaging, and drug-binding DNA motifs for drug delivery. The sizes of these NFs can be tuned down to approximately 200 nm in diameter. The hierarchical internal porous structures and densely packed drug-binding DNA motifs in NFs endow them with drug loading capacity as high as 71.4% (wt/wt). Dox-loaded NFs (NF-Dox) were stable at physiological pH (7.4), yet they gradually released drugs under either acidic or basic conditions. The aptamers allowed NF-Dox to deliver Dox into both target chemosensitive cancer cells and target MDR cells. NFs protected drugs from efflux and enhanced drug accumulation and retention in MDR cells. As a result, NF-Dox induced potent cytotoxicity in both target chemosensitive cancer cells and MDR cells, but not in nontarget cells, thus circumventing MDR and reducing the side effects in nontarget cells. These results indicate that NFs can be used as a platform for circumventing drug resistance during targeted anticancer drug delivery.
Experimental details
2.1 Self-assembly of DNA NFs using RCR Phosphorylated DNA templates (0.6 μM) and the corresponding primers (1.2 μM) were mixed and annealed in DNA ligation buffer (5 mM Tris-HCl, 1 mM MgCl 2 , 0.1 mM ATP, and 1 mM dithiothreitol) by heating at 95 °C for 2 min followed by gradual cooling to room temperature over 3 h. Linear templates were circularized using T4 DNA ligase (10 U/μL, New England Biolabs, Ipswich, MA, USA; reaction at room temperature, 3 h). To prepare NFs, circularized templates (0.3 μM) were incubated with Φ29 DNA polymerase (2 U/μL), dNTPs (each 2 mM/μL), and BSA (1) in buffer solution (50 mM Tris-HCl, 10 mM (NH 4 ) 2 SO 4 , 10 mM MgCl 2 , and 4 mM dithiothreitol) (New England Biolabs) at 30 °C for a specified time. The reaction was terminated by heating at 75 °C for 10 min. NFs were washed with Dulbecco's PBS, precipitated by centrifugation, and stored at 4 °C until use.
Drug accumulation and retention in cancer cells by flow cytometry
Drug delivery was also evaluated using flow cytometry. Specifically, cells were again treated with free Dox or NF-Dox, as in the confocal microscopy study. After incubation for 3 h, cells were trypsinized (for MCF7 cells and MCF7/MDR cells) to single cells, washed, and analyzed by flow cytometry to determine Dox fluorescence intensities. To study drug retention in cancer cells, the treated cells were washed to remove Dox or NF-Dox, followed by further culturing cells for different lengths of time. The resulting cells were again trypsinized (for MCF7 cells and MCF7/MDR cells), washed twice with Dulbecco's PBS, and analyzed by flow cytometry to determine Dox fluorescence intensities to determine the Dox retention in cells.
Cytotoxicity assays
Cytotoxicity was evaluated using a CellTiter 96 cell proliferation assay (MTS assay) (Promega, Madison, WI, USA). Cells were treated with NFs, free Dox, or NF-Dox complexes in fetal bovine serum (FBS)-free medium. After incubation for 3 h in a cell culture incubator, the supernatant was removed and fresh medium containing 150 μL FBS was added to the cells for further cell growth (48 h). Next, the medium was again removed and CellTiter reagent (20 μL) diluted in fresh FBS-free medium (100 μL) was added to each well and incubated for 1-2 h. The absorbance (490 nm) of the resulting solution was recorded using a microplate reader (Tecan Safire microplate reader, AG, Mannedorf, Switzerland), and cell viability was determined according to the manufacturer's instructions. The results were fitted to a dose-response model using software Origin 8 (Northampton, MA, USA).
Results and discussion

Self-assembly of multifunctional NFs
The programmability of DNA and the sequenceindependence of NF assembly enabled incorporation of functional DNA moieties into NFs simply by designing the RCR DNA templates. For targeted drug delivery, NFs were modularly incorporated with DNA aptamers for specific recognition of cancer cells and drug-binding DNA motifs for drug delivery (Fig. 1) . In this study, aptamers KK1B10 (KK) [16] and sgc8 [15] were chosen for leukemia and breast cancer cell models, respectively. Dox, which is widely used in cancer therapy but often shows drug resistance, was used [5] . We first studied aptamer KK to assemble KK-integrated nanoflowers (KK-NFs) for Dox delivery into leukemia K562 cells (chemosensitive) and the corresponding K562/MDR cells. The RCR template, T-KK, was designed to encode DNA with alternative KK and Dox-binding DNA motifs, which are tandem GCs or CGs in double-stranded DNA for Dox intercalation (Table S1 and Fig. S1 in the Electronic Supplementary Material (ESM)) [39] .
To generate DNA by the RCR reaction, phosphorylated linear templates were circularized using DNA ligase and a ligation template, which also served as the primer for downstream RCR catalyzed by Φ29 DNA polymerase. Efficient production of DNA by Figure 1 Schematic illustration of multifunctional DNA NFs as nanocarriers to circumvent MDR cells in targeted drug delivery. NFs were self-assembled from DNA and magnesium pyrophosphate generated from RCR, for which the DNA templates encoded aptamers and drug-binding DNA motifs. Drugs (Dox) were loaded into NFs via both DNA-binding motifs and physical encapsulation. NFs mediated the specific recognition, internalization, and targeted drug delivery to both chemosensitive and MDR cancer cells. NF-Dox was relatively stable at physiological pH, thus avoiding rapid drug release and allowing for controlled drug release. In target MDR cells (depicted), NF-Dox was internalized and transported to the cytosol, during which NFs protected Dox from efflux by P-gp, in contrast to rapid efflux of free Dox by adjacent P-gp. In the cytosol, gradually released drugs evaded efflux because of the absence of P-gp. Thus, NF-Dox enhanced drug delivery into subcellular target organelles (e.g., nucleus), promoting the cytotoxicity in MDR cells and circumventing drug resistance in targeted cancer therapy. Nano Res. 2015, 8(11): 3447-3460 RCR, as verified by gel electrophoresis (Fig. S2 in the ESM), resulted in an increased local DNA mass concentration and eventually led to formation of NFs. By scanning electron microscopy (SEM), monodispersed spherical NFs were observed to have diameters of approximately 200 nm after the RCR reaction for 3 h (Fig. 2(a) ). Hierarchical pores, which are thought to encapsulate drugs and protect the drugs in NFs, were also observed in KK-NFs. Dynamic light scattering (DLS) confirmed the diameter of KK-NFs in bulk solution to be 230 ± 30 nm (mean ± SD) ( Fig. 2(b) ). The larger size observed by DLS compared to SEM images was most likely a result of the larger hydrodynamic size than dry NFs for SEM imaging. Based on the EPR effect, nanocarriers of this size are expected to penetrate leaky blood vasculature and be retained in tumors for a prolonged time. We observed that NF size could be influenced by the activity of Φ29, and the size was confirmed for each batch of enzyme.
To quantify DNA concentration in NFs, we measured the absorbance of remnant dNTP at 260 nm, calculated the amount of consumed dNTP, and determined that 52.6% of dNTP was consumed after RCR for 3 h. Thus, on average, 76 copies of DNA were produced for each template (Table S2 in the ESM) based on the amount of consumed dNTP and the number of nucleotides in one template (92 nucleotides in KK-T). NF sizes increased progressively with longer RCR time (Fig. S3 in the ESM), with diameters of approximately 1 μm after the RCR reaction for 10 h (Fig. 2(c) ). The products after RCR for n hours are denoted as RCR n and NFs with diameters of m nm are denoted as NF m . Within the same time period of RCR, NF sizes were larger than those observed previously using another RCR template, presumably because of lower topological constraints or higher enzymatic activities in the present study [37] . Under polarized optical microscopy, birefringent spherulite NFs were observed ( Fig. 2(d) ), verifying that NFs were anisotropic and liquid crystalline. Furthermore, NFs showed high resistance to nuclease cleavage, as indicated by the morphological integrity of NFs treated with DNase I at 5 U/mL, a concentration considerably higher than that in human blood (< 1 U/mL) [40] (Fig. 2(e) ). Moreover, we previously demonstrated that DNA NFs were also resistant to degradation by human serum or denaturation by urea, heating, or extreme dilution mimicking of drug administration into blood circulation. The excellent stability makes NFs promising for drug delivery, where NFs may encounter ubiquitous nucleases and are diluted in the circulatory system. Because of its small size, KK-NF 200 was used for subsequent studies.
Similarly, aptamer sgc8 was integrated into NFs (S-NFs) for chemosensitive breast cancer MCF7 cells, as well as MCF7/MDR cells developed by transducing MCF7 cells with the MDR1 gene for the overexpression of P-gp [41] . Flow cytometry confirmed sgc8 for selective recognition of both MCF7 and MCF7/MDR cells. Again, using the design of the RCR template, S-T (Table S1 in the ESM), aptamers, and drug-binding motifs were incorporated into S-NFs. SEM imaging revealed the diameters of S-NFs (~200 nm) after the RCR reaction for 6 h and the stability under DNase I treatment (Fig. S4 in the ESM).
Drug loading into NFs and controlled drug release from NFs
NFs were then studied in vitro as nanocarriers for drug loading and conditionally released drugs from NFs. To load drugs into NFs, Dox was incubated with NFs, followed by centrifugation to remove free Dox and quantification of Dox loaded into NFs (Fig. S5(a) in the ESM). Dox was rapidly loaded into NFs, reaching a plateau within 30 min (Fig. S5(b) in the ESM for KK-NFs as an example). SEM imaging verified the morphological integrity of Dox-loaded KK-NFs (KK-NF-Dox) (Fig. S5(c) in the ESM). The Dox loading capacity was determined to be 71.4% (wt/wt) (see calculation in Table S3 in the ESM), which is very high. The high drug loading capacity was attributed to both the densely packed drug-binding DNA motifs in NFs and the internal porous structures in NFs for physical encapsulation. Since a maximum of 12 Doxbinding sites could be formed in one RCR replicate, by calculation, a maximum of 34.3% Dox in NF-Dox was loaded by specific DNA-binding, while the remainder of Dox was likely loaded via physical encapsulation into porous structures in NFs (Table S3 in the ESM). The high drug loading capacity by physical encapsulation in NFs makes it possible to load and deliver non-DNA-binding drugs as well using NFs. Overall, this high drug loading capacity makes NFs excellent drug carriers.
The stability of NF-Dox was then evaluated under physiological conditions and controlled drug release. Given the central role of pH in physiological regulation, we studied the influence of pH on the stability and drug release of NF-Dox using dialysis. Since the trace amount of released Dox over a relatively short time could not be accurately quantified based on Dox absorbance, we quantified Dox release by measuring Dox fluorescence intensities. Since Dox fluorescence can vary at different pH conditions or after incubation in buffer solution for different times, we calibrated Dox fluorescence intensities vs. Dox concentrations by measuring the fluorescence intensities of Dox in a series of concentrations at different pH (5, 7.4, and 9) and after incubation in buffer for different times. Fluorescence intensities were then plotted as a function of Dox concentrations for different pH and different incubation times, respectively (Fig. S6 in the ESM) . The results showed that incubation time had a negligible influence on Dox fluorescence intensities. A linear relationship between Dox concentrations and fluorescence intensities was found at Dox concentrations ranging from 0.1-10 μM, where Dox concentrations and fluorescence intensities for each pH condition were fit into functions. Based on this, the amount of released Dox was determined by measuring Dox fluorescence intensities. Dox release kinetics was then studied. For example, KK-NF-Dox was dialyzed at pH 5, 7.4, and 9, followed by quantification of released Dox at a series of time points. Dox release was well-fit to a drug release model for each pH (Fig. 2(f) ). At pH 7.4, KK-NF-Dox was stable and Dox release from NF-Dox was relatively slow, in contrast to the rapid release of free Dox at equivalent concentrations (as a positive control) from dialysis units. At both pH 5 and 9, Dox release was Nano Res. 2015, 8(11): 3447-3460 greatly enhanced, at rates approximately half that of free Dox diffusion. The facilitated drug release likely occurred because acidic or basic conditions induced changes in DNA conformations, DNA-drug interactions, and NF structures. The plateau of drug release was lower than 100%, most likely because drug release reached equilibrium or the dialysis membrane was partially blocked after immersing in drug solution for a long period. Most extra-/intracellular fluid is regulated at or near pH 7.4, at which relatively high stability of NF-Dox was expected to: 1) ensure the integrity of NF-Dox and prevent Dox from being rapidly released before diffusing away from the vicinity of cell membrane over a relative short time period, thus avoiding efflux of Dox released from NFs by P-gp on an adjacent cell membrane and 2) allow for the controlled (gradual) release [42] of Dox from NFs when NF-Dox stays away from cell membrane in the cytosol during a relatively long time period, and the gradually released Dox would avoid efflux by P-gp. Furthermore, Dox release may be facilitated if it is transported into acidic subcellular organelles, such as the endosome and the lysosome.
Selective recognition and internalization of NFs to target cancer cells
With high drug loading capacity, NFs were tested for specific cancer cell recognition for targeted drug delivery. Specifically, we incorporated Cy5 into NFs by supplementing dNTPs with Cy5-dUTP, which can be enzymatically incorporated into NFs during RCR. Flow cytometry verified that Cy5-labeled KK-NFs specifically recognized target leukemia K562 and K562/MDR cells, but not nontarget Ramos cells (Figs. 3(a)  and 3(c) ). Similarly, Cy5-labeled S-NFs were specifically bound to target human breast cancer MCF7 and MCF7/MDR cells, but not nontarget Ramos cells (Figs. 3(b) and 3(c) ). To study the recognition specificity of NFs, we prepared another NF using a control DNA template, in which a non-aptamer control DNA substituted the aptamer-encoding sequences in KK-T (Table S1 ). The resulting ctrl-NFs (SEM images in Fig. S7(a) in the ESM) did not specifically bind to K562, K562/MDR, MCF7, or MCF7/MDR cells (Figs. S7(b) and S7(c) in the ESM). These results demonstrated that the aptamer in NFs maintained their ability to specifically recognize cancer cells, allowing NFs to serve as nanocarriers for targeted drug delivery.
For efficient drug delivery, it is also desirable for nanocarriers to be internalized into cells. We thus studied the internalization of Cy5-labeled NFs into cancer cells using confocal laser scanning microscopy. After incubation of NFs with the corresponding target cancer cells for 3 h, strong Cy5 fluorescence intensity was observed in both chemosensitive cells and MDR cells (KK-NFs for K562 cells and K562/MDR cells (Fig. 4(a) ); and S-NFs for MCF7 cells and MCF7/MDR cells (Fig. 4(b)) ). Compared to DNA nanostructures without aptamers, which can also be internalized into cells over a relatively long period of time (e.g., 24 h) [22] , the aptamer moieties in NFs appeared to enhance the internalization of NFs, indicating the potential of NFs for efficient drug delivery. 
Intracellular drug delivery, accumulation, and retention in cancer cells
With the high drug payload capacity of NFs, high stability of NF-Dox complexes, and controlled drug release from NF-Dox, NFs were next studied as nanocarriers for targeted drug delivery into both chemosensitive and the corresponding MDR cancer cells. Overexpression of P-gp, which has been reported to release many types of drugs from MDR cells, was verified by flow cytometry (Fig. S8 in the ESM) . Confocal microscopy was used to visualize the fluorescence of intracellular Dox. Specifically, K562 and K562/MDR were treated with free Dox and KK-NF-Dox, respectively, followed by incubation for 3 h. Hoechst 33342 was used to identify the cell nucleus. Strong Dox fluorescence intensity was observed in chemosensitive K562 cells treated with either free Dox or KK-NF-Dox (Fig. 5(a) ), indicating that free Dox rapidly entered cells by passive diffusion and with free Dox and the corresponding NF-Dox, respectively, for 3 h and the cells were washed to remove treatment, which was followed by further incubation. Dox fluorescence intensities of the resulting cells were analyzed by flow cytometry at different time points. When treated with free Dox, chemosensitive cells exhibited nearly constant fluorescence intensities over 4 h after removal of extracellular drugs (Fig. 6(a) for K562 cells, and Fig. 6(c) for MCF7 cells), whereas Dox fluorescence intensities in MDR cells treated with free Dox were gradually decreased (Fig. 6(b) for K562/MDR cells, and Fig. 6(d) for MCF7/MDR cells). In contrast, when treated with the corresponding aptamer-NFDox, both chemosensitive and MDR cells maintained high Dox fluorescence intensities; importantly, the Dox fluorescence intensities in MDR cells decreased relatively slowly, compared to these cells treated with free Dox. The enhanced accumulation and retention of Dox delivered by NFs in MDR cells likely resulted from protection against efflux by P-gp at physiological pH (7.4). 
Circumvention of MDR by NF-mediated targeted drug delivery
We then evaluated whether the prepared NFs could circumvent drug resistance in targeted therapy. Both chemosensitive cells and the corresponding MDR cells were treated with (1) free Dox, (2) ctrl-NF-Dox, and (3) the corresponding aptamer-NF-Dox. After incubation for 3 h to allow permeation or internalization of Dox or NF-Dox into cells, treatment was removed and cells were cultured for 2 days, followed by an MTS assay to determine cell viability. In chemosensitive cancer cells, both free Dox and aptamer-NF-Dox induced potent cytotoxicity ( Fig. 7(a) for K562 cells and Fig. 7(d) for MCF7 cells) . In contrast, in MDR cells, while free Dox induced only slight cytotoxicity, the corresponding aptamer-NF-Dox dramatically decreased cell viability (Fig. 7(b) for K562/ MDR cells and Fig. 7 (e) for MCF7/MDR cells). In particular, in K562 chemosensitive cells, the IC 50 of free Dox, ctrl-NF-Dox, and S-NF-Dox were 4.5 μM, > 50 μM, and 5.1 μM, respectively; in K562/MDR cells, while the IC 50 of free Dox, ctrl-NF-Dox, and S-NF-Dox were > 50 μM, > 50 μM, and 13.2 μM, respectively; in MCF7 chemosensitive cells, the IC 50 of free Dox, Ctrl-NF-Dox, and S-NF-Dox are 4.2 μM, > 50 μM, and 3.7 μM, (Fig. 7(c) for K562/ MDR cells as an example). However, in nontarget Ramos cells, both KK-NF-Dox and S-NF-Dox induced dramatically less cytotoxicity than free Dox, indicating the selectivity of cytotoxicity mediated by the aptamer-NF-Dox (Fig. 7(f) ). Furthermore, ctrl-NF-Dox, which did not specifically recognize cancer cells, induced only slight toxicity at high dosages, further demonstrating the selectivity of NF-mediated drug delivery. Pure NFs did not induce apparent cytotoxicity, verifying their biocompatibility at the cellular level (Fig. S9 in 
Conclusions
We demonstrated the use of multifunctional DNA NFs for circumventing drug resistance in targeted anticancer drug delivery in both leukemia and breast cancer cell models. DNA NFs were self-assembled from DNA and magnesium pyrophosphate generated during RCR. NF assembly avoids the otherwise complicated sequence design in conventional assembly of DNA nanostructures and makes it easy to incorporate functionalities such as aptamers for specific cancer cell targeting, fluorophores for molecular imaging, and drug-binding DNA sequences for specific drug intercalation during drug delivery. Therapeutic functionalities, such as DNA antisense [43] and immunomodulatory DNA, [44] could also be simultaneously integrated into NFs and will be reported in future studies. Particularly, in this study, NFs were incorporated with different aptamers for specific recognition of both chemosensitive cancer cells and MDR cells during targeted drug delivery.
Combining the high density of drug-binding DNA motifs and porous DNA structures in NFs, NFs were endowed with dual-mode high drug loading capacity. Specifically, the Dox loading efficiency of KK-NFs was as high as 71.4% (wt/wt). Furthermore, we estimated that up to 34.3% Dox in NF-Dox could be loaded by intercalation into drug-binding motifs, and the remainder of Dox was likely loaded via physical encapsulation into the porous structures in NFs, indicating that NFs also likely serve as carriers for drugs that cannot specifically bind to DNA. NFs have high biostability and dramatically resisted nuclease degradation. NF-Dox complexes were relatively stable at physiological pH, with Dox slowly released from NFs, avoiding rapid drug efflux by P-gp on adjacent cell membranes during the short time period before NF-Dox diffuses from the vicinity of the cell membrane to the cytosol and allowing for controlled drug release during a relatively long time period when NF-Dox stays in the inner cytosol. Furthermore, Dox release from NF-Dox was facilitated under either acidic or basic conditions, making it possible to facilitate drug release when transported into acidic subcellular organelles, such as the lysosome and the endosome. In contrast to free Dox, which can only efficiently diffuse into chemosensitive cells, NFs efficiently delivered and retained Dox in both chemosensitive cells and MDR cells, and thus selectively inhibited cell proliferation in both target chemosensitive cells and target MDR cells, but not in nontarget Ramos cells or by non-targeting ctrl-NFs. Overall, DNA NFs are promising for the circumvention of MDR in targeted drug delivery and present tremendous clinical significance, as drug resistance and drug toxicity are two major hurdles in cancer therapy.
